Ki 23057 is a competitive, orally active inhibitor for tyrosine kinase , which inhibits the phosphorylation of K-samII/FGF-R2 , VEGF-R1, VEGF-R2, PDGF-Rβ and c-Kit , with IC 50 s of 88, 69, 83, 100 and 480 nM. Ki 23057 inhibits the proliferation of sclerogastric cancer cells OCUM-2MD3 and OCUM-8, and induces apoptosis . Ki 23057 exhibits antitumor efficacy in mouse models.
Products | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.